Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
about
Progress and problems with the use of suicide genes for targeted cancer therapyCharacterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of Helicobacter pylori.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.A mammalianized synthetic nitroreductase gene for high-level expressionProdrugs for improving tumor targetability and efficiency.Current status and prospects for gene therapy.Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.Gene therapy and virotherapy of gastric cancer: preclinical results and clinical developments.Gene- and immunotherapy for hepatocellular carcinoma.Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.Gene therapy targeting to tumor endothelium.p53 gene in treatment of hepatic carcinoma: status quo.Drug metabolism by tumours: its nature, relevance and therapeutic implications.E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954Specifically targeted gene therapy for small-cell lung cancer.Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics.Suicide gene therapy for graft-versus-host disease.Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Update on oncolytic viral therapy - targeting angiogenesisGene-directed enzyme prodrug therapy.Targeted prodrug approaches for hormone refractory prostate cancer.Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.Enriching suicide gene bearing tumor cells for an increased bystander effect.Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.Gene therapy of liver cancer.Quinone oxidoreductase-2-mediated prodrug cancer therapy.Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer.Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.Factors influencing retention of adenovirus within tumours following direct intratumoural injection.Is gene therapy the answer for prostate cancer?Heterologous Overexpression and Biochemical Characterization of a Nitroreductase from Gluconobacter oxydans 621H.
P2860
Q28262370-8D9AEA12-1D1F-413F-87BA-AD3C175D2F91Q30437743-5A8CB4E1-3DD7-415E-B185-9328E2467F5EQ33230098-8A1E32B9-1CC5-4724-B815-EFE97E60637EQ33497608-D1DC5CFD-B5B9-4068-81D8-0B75527DB03DQ35095165-25EEA4A1-0066-45A9-85CA-3AA84158C103Q35881934-D97C47D5-6756-4119-AD7F-0327FAB82F9FQ35964830-4EA9A0CA-4F07-4CF0-AC4A-D12488DEB34EQ36090054-9C1FE0B5-4050-4DF9-8BDE-E8AFB7078539Q36150432-490EA925-71FB-4E7C-80DE-DC18D22054FAQ36303872-88DBB8C7-B467-43EA-94C2-D62BB325EBF9Q36649681-1FE6E704-9A40-4208-BD50-1395A5E32F7AQ36764842-D39FE275-E725-444B-A543-A47A3039EAFBQ37008879-9A2B8F46-21DB-4CCC-90F9-3DB178694352Q37212365-564CB785-031E-4BEA-8686-FA2B91090F96Q37449030-AC80C919-5027-4F97-BD1B-476D7EBC9C40Q37638585-FAB42A63-3AAA-4F0E-944A-A6B54191022AQ37773293-4C5F5717-C3C2-416A-9F5B-DB832D087427Q38099680-46C049BF-511F-40FE-B879-4C510F10C1DBQ38128561-CB291421-89F2-49F1-B878-A934C9BEBBEBQ38262019-24B9BECB-8724-4A9A-9223-2C3524199410Q38295983-4E24012D-5046-4CE4-B348-1BE92672ED61Q39292898-E539098D-CCC2-4C83-A786-679825A49E0DQ39507151-B462C249-F7C6-4E9D-90ED-4744E100289DQ39508417-F5F5ED1B-BB04-4497-9429-24CE4F2CDF3BQ39848249-83F076ED-3F79-4852-AA2E-8505B6229EC9Q40035482-3F005D38-FF8B-4D8C-A526-A2CA32061041Q40170852-8785105C-500F-4EB4-AE5F-C5809B6D837AQ40223019-847F6887-F367-4BA0-9F26-1C16A1966445Q40440798-30BBE8FF-0F00-4612-9EB2-0E0513833F06Q42726362-40F4982E-A8D3-4008-B45C-C73720AF02C8Q42970315-AC7F0EF2-C02A-4090-9FF6-EFE2DEFEBA55Q43895807-319A3955-BB89-40E4-8B38-5BB99D0AC6C3Q45235059-02C865E1-1C71-4E4F-B0D9-2CB6E6D7D81FQ45875328-7C07F57F-3E46-4F9F-8A4E-927DD9653567Q45877911-E2440005-4F94-4D9D-8EB2-408389A1DF8BQ51347749-EFB05B85-B3C8-48EE-9B35-20A4FF09B8D3
P2860
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@en
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@nl
type
label
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@en
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@nl
prefLabel
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@en
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@nl
P2093
P356
P1476
Virus-directed enzyme prodrug ...... with resectable liver cancer.
@en
P2093
Andrew Mountain
Daniel H Palmer
Darius Mirza
David J Kerr
Diana Hull
Gary Reynolds
John Ellis
Joost R M van der Sijp
Lawrence S Young
Mark Horne
P304
P356
10.1200/JCO.2004.10.005
P407
P577
2004-03-29T00:00:00Z